Funding Opportunity RFA-CA-21-038 from the NIH Guide for Grants and Contracts. The overall goal of this FOA and the companion FOA is to establish an agile and effective network infrastructure that undertakes collaborative research to discover molecularly or immunologically targeted agents designed to prevent or intercept oncogenic process in high-risk populations for precision cancer prevention and interception.

Funding Opportunity RFA-CA-21-039 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit Applications for the Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC) (U24). The overall goal of this FOA and the companion FOA (U54 CAP-IT Specialized Centers hyperlink to be inserted) is to establish an agile and effective network infrastructure to undertake collaborative research focusing on precision cancer prevention and interception, with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations. The CAP-IT network will be formed by up to three U54 Specialized Centers (the companion FOA [hyperlink to be inserted] and one U24 CAP-IT DRCC (this FOA). The CAP-IT DRCC will function as the Programs centralized data management and network activity coordination center.

Competitive Salary: EMBL: We are seeking a faculty-level genome scientist to lead the Eukaryotic Annotation Team at the European Molecular Biology Laboratory’s European Bioinfo Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: We are looking for a postdoctoral-level scientist to join a new international collaborative project, “ProID”, funded by the European Commission, to cr Hinxton, Cambridgeshire, England

Funding Opportunity PAR-21-265 from the NIH Guide for Grants and Contracts. (Reissue of PAR-18-665) This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support clinical trials for projects that were previously funded by NIH SBIR and STTR Phase II awards. The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Since conducting the clinical trials needed for commercialization may be capital-intensive, the FOA aims to facilitate the transition of SBIR Phase II projects to the commercialization stage by promoting partnerships between NIH's SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period.

Funding Opportunity PAR-21-266 from the NIH Guide for Grants and Contracts. (Reissue of PAR-18-618) The purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Only SBIR Phase II and Fast-Track applications are supported under this program. SBIR Phase I applications are only accepted as part of a Fast-track application.

Funding Opportunity RFA-AG-22-015 from the NIH Guide for Grants and Contracts. The overarching objective of this funding opportunity announcement (FOA) is to develop and strengthen animal models for behavioral and social research in the interest of furthering the mechanistic understanding of how social and physical environmental factors contribute to aging processes and the etiology and progression of age-related conditions and diseases.

Notice NOT-AA-21-038 from the NIH Guide for Grants and Contracts

Notice NOT-AR-21-025 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-152 from the NIH Guide for Grants and Contracts

Notice NOT-AR-21-024 from the NIH Guide for Grants and Contracts

Notice NOT-AR-21-022 from the NIH Guide for Grants and Contracts

Notice NOT-DE-21-007 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-22-024 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support research that can lead to the development of evidence-based primary care screening tools and behavioral interventions to prevent abuse in at-risk older and vulnerable adults with mild cognitive impairment (MCI) and Alzheimers disease and Alzheimer's disease-related dementias (AD/ADRD) and their families.

Participating in these activities doesn’t result in fewer publications or longer times to graduation

This scientist took his career in an unexpected direction after weighing the realities of pursuing an academic career path

Notice NOT-NS-21-077 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-096 from the NIH Guide for Grants and Contracts

Notice NOT-DA-21-002 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-003 from the NIH Guide for Grants and Contracts